Breaking News
Amedisys Names Scott Ginn Acting Chief Operating Officer
Amedisys, a leading provider of home health, hospice, personal care and high-acuity care, names Scott Ginn, Executive Vice President and Chief Financial Officer, its Acting Chief Operating Officer, effective immediately.
“I am delighted to have Scott Ginn serving as a trusted partner in this critical role on our leadership team,” stated Paul Kusserow, Chairman and CEO of Amedisys. “Scott is well respected within Amedisys and the industry and this appointment will generate enormous enthusiasm. I am fully confident that his intimate knowledge of both Amedisys’ finance and operations will enable us to deliver strong results and continue to provide the industry’s best care to our people and our patients.”
Ginn has led financial teams at Amedisys since 2007, serving as Senior Vice President of Accounting and Controller and Chief Accounting Officer before being named Chief Financial Officer in 2017 and then being promoted to Executive Vice President in 2021. As Acting Chief Operating Officer, Ginn will be responsible for all of Amedisys’ home health, hospice and personal care operations in addition to his current duties as Chief Financial Officer.
“I am proud to step into this position and to continue to lead the company I’ve had the privilege of serving for 15 years,” stated Scott Ginn, Executive Vice President, Chief Financial Officer and Acting Chief Operating Officer. “I look forward to working more closely with our operators and capitalizing on the tremendous amount of opportunity ahead of us.”
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more